Why J&J Still Wants In On Atopic Dermatitis

The immunology company has used business development to bring in atopic dermatitis bispecific antibodies. J&J VP-immunodermatology disease area leader Liza O’Dowd talked to Scrip about the developments.

(Shutterstock)

More from Interviews

More from R&D